Vyleesi Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling their Vyleesi (bremelanotide) prescriptions, they're encountering a real and well-documented access challenge. While Vyleesi is not in a formal FDA-reported shortage, its specialty pharmacy-only distribution model — combined with insurance prior authorization requirements and high cash pricing — creates a de facto access gap that directly affects patient adherence and treatment outcomes.

This briefing covers the current Vyleesi availability landscape, prescribing and documentation considerations, cost and access pathways, and tools that can help your patients access the medication you've prescribed.

Current Availability Status (2026)

As of 2026, Vyleesi is not listed on the FDA Drug Shortage database. Cosette Pharmaceuticals has not reported manufacturing disruptions. The drug remains FDA-approved and commercially available through specialty pharmacy channels.

The access challenges your patients face are structural rather than supply-based:

• Specialty pharmacy-only: Vyleesi must be e-prescribed to a designated specialty pharmacy. Standard retail pharmacies cannot fulfill these prescriptions.
• Prior authorization: Most major commercial insurers — including UnitedHealthcare and Cigna — require PA with documentation of HSDD diagnosis and clinical criteria.
• High cash price: Approximately $290 per single autoinjector; $1,295+ for a pack of 4. The monthly maximum of 8 doses exceeds $2,000 at retail.
• No generic available: The earliest estimated generic entry is November 2033. Until then, brand-name Vyleesi is the only FDA-approved bremelanotide autoinjector.

Prescribing Considerations for Vyleesi in 2026

Vyleesi is indicated for premenopausal women with acquired, generalized HSDD — defined as low sexual desire that causes marked distress or interpersonal difficulty and is NOT attributable to a co-existing medical or psychiatric condition, relationship problems, or medication effects.

Key prescribing notes for 2026:

• Vyleesi is NOT indicated for postmenopausal women or for men (off-label use for these populations exists but is outside the FDA indication).
• No REMS program is in place for Vyleesi. Any licensed prescriber can write a prescription.
• Use ICD-10-CM code F52.0 for HSDD. HSDD is miscoded over one-third of the time — correct coding is essential for PA approval.
• Cardiovascular considerations: Vyleesi transiently increases blood pressure and decreases heart rate after each dose. It is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Ensure BP is well-controlled before initiating.
• Contraception: Advise patients of reproductive potential to use effective contraception while on Vyleesi. Discontinue if pregnancy is suspected.
• Drug interactions: Vyleesi significantly decreases systemic exposure of orally-administered naltrexone. Avoid concomitant use with oral naltrexone-containing products. Monitor any co-administered oral medications, as Vyleesi slows gastric motility.

Prior Authorization: What Insurers Require

PA requirements vary by payer but generally include:

• Confirmed diagnosis of acquired, generalized HSDD (ICD-10 F52.0) in a premenopausal woman
• Documentation that low desire causes marked distress or interpersonal difficulty
• Confirmation that HSDD is not due to a co-existing medical or psychiatric condition, relationship problems, or medication effects
• Absence of contraindications (uncontrolled hypertension, cardiovascular disease)

For reauthorization, insurers typically also require documentation of positive clinical response to Vyleesi therapy. Proactively document improvements in desire scores and distress at follow-up visits.

Managing Nausea: The Most Common Discontinuation Reason

Nausea is the most frequently reported adverse event with Vyleesi, affecting approximately 40% of patients — particularly with the first injection. It leads to premature discontinuation in about 8% of patients. To improve tolerability and retention:

• Counsel patients that nausea often improves significantly with the second dose
• Consider co-prescribing an anti-emetic (ondansetron, promethazine) for the first 1–2 uses
• Advise patients to inject at least 45 minutes before activity and to eat a light meal if nausea has been an issue

Patient Cost and Access Tools

For commercially insured patients: Direct them to Cosette's BlinkRx Copay Assistance program (1-833-799-5028 or vyleesi.com/getting-started). Eligible patients may pay as little as $0. The program covers copay, coinsurance, and deductibles and applies to up to 2 fills per 30 days.

For patients on government insurance: The manufacturer copay program does not apply to Medicaid, TRICARE, or Medicare patients. Discuss alternatives with these patients, including Addyi (flibanserin) or off-label options like low-dose testosterone.

For patients struggling to locate a specialty pharmacy that can fill Vyleesi near them, medfinder for providers can help streamline your workflow by identifying which pharmacies have the medication available without your staff spending time on hold.

When to Consider Alternatives

If a patient is unable to access Vyleesi after reasonable attempts — due to insurance denial, cost, or persistent routing issues — consider Addyi (flibanserin), which was recently expanded to include all women under 65, or off-label low-dose testosterone. See our full provider guide to helping patients find Vyleesi in stock for more detail.